Wanbury
278.90
+1.25(+0.45%)
Market Cap₹913.97 Cr
PE Ratio21.34
IndustryHealthcare
Company Performance:
1D+0.45%
1M+4.91%
6M+48.12%
1Y+15.90%
5Y+613.30%
View Company Insightsright
Latest news about Wanbury
Wanbury's Q1 Profit Soars to ₹135 Crore, Revenue Climbs to ₹1.6 Billion Aug 05, 2025
Wanbury Limited's Q1 consolidated net profit surged to ₹135.00 crore from ₹10.40 crore year-over-year. Revenue grew 23% to ₹1.60 billion. EBITDA more than doubled to ₹244.00 crore, with margin expanding to 14.98%. Standalone results show profit after tax increasing by over 1200% year-over-year.
Wanbury Limited Reports Strong Q1 Results, Approves ESOP Grants and Director Reappointment Aug 04, 2025
Wanbury Unveils 'Wanbury Cred': A Revolutionary Iron Supplement to Combat Anemia Jun 27, 2025
Wanbury Secures Brazilian FDA Approval for Maharashtra Manufacturing Facility May 20, 2025
Wanbury Limited Embarks on Digital Transformation with SAP S/4 HANA Implementation Apr 23, 2025
More news about Wanbury
06Mar 25
Wanbury Limited Slashes Interest Costs with ₹175 Crore Debt Refinancing
Wanbury Limited has successfully refinanced ₹175 crore of existing debt through Emerging India Credit Opportunities Fund II. The new deal features a 12.5% per annum interest rate, down from 21% on previous NCDs, with a 5-year tenure and 9-month moratorium. The refinancing includes repurchase of ₹95 crore NCDs and refinancing of ₹150 crore existing debt. This move is expected to significantly reduce Wanbury's interest burden and improve its financial health.
Wanbury
278.90
+1.25
(+0.45%)
1 Year Returns:+15.90%
Industry Peers
Sun Pharmaceutical
1,593.60
(+0.71%)
Divis Laboratories
6,009.00
(-2.03%)
Cipla
1,553.40
(-1.55%)
Torrent Pharmaceuticals
3,579.10
(-0.56%)
Dr Reddys Laboratories
1,268.10
(+1.21%)
Mankind Pharma
2,550.60
(-0.71%)
Zydus Life Science
1,013.85
(+0.19%)
Lupin
1,943.90
(+0.24%)
Abbott
31,150.00
(-3.19%)
Alkem Laboratories
5,333.50
(+0.60%)